InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2021-07-02 | Marie Newman | house | Purchase | $15,001 - $50,000 |
| 2019-06-24 | Donna Shalala | house | Sale | $1,001 - $15,000 |
| 2019-06-19 | Donna Shalala | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net revenues | $655.4M+8.3% | $605.2M+18.8% | $509.3M-5.3% | $537.8M+0.5% | $535.0M |
| Cost of revenues | $166.9M+21.6% | $137.2M+6.9% | $128.3M+11.7% | $114.9M-0.0% | $114.9M |
| Gross profit | $488.5M+4.4% | $468.0M+22.8% | $381.1M-9.9% | $423.0M+0.7% | $420.2M |
| Research, development and clinical studies | $224.5M+7.1% | $209.6M-6.0% | $223.1M+8.2% | $206.1M+2.4% | $201.3M |
| Sales and marketing | $240.1M+0.4% | $239.1M+5.4% | $226.8M+30.6% | $173.7M+26.7% | $137.1M |
| General and administrative | $177.7M-6.4% | $189.8M+15.7% | $164.1M+23.6% | $132.8M+5.3% | $126.1M |
| Total operating costs and expenses | $642.3M+0.6% | $638.5M+4.0% | $613.9M+19.8% | $512.5M+10.3% | $464.5M |
| Operating income (loss) | -$153.8M+9.8% | -$170.5M+26.8% | -$232.9M-160.1% | -$89.5M-101.9% | -$44.3M |
| Financial (expenses) income, net | $17.6M-55.4% | $39.3M-4.4% | $41.1M+435.8% | $7.7M+199.2% | -$7.7M |
| Total income (loss) before income taxes | -$136.3M-3.9% | -$131.2M+31.6% | -$191.7M-134.3% | -$81.8M-57.2% | -$52.1M |
| Income tax | -$23K-100.1% | $37.5M+144.8% | $15.3M+43.2% | $10.7M+70.3% | $6.3M |
| Net income (loss) | -$136.2M+19.2% | -$168.6M+18.6% | -$207.0M-123.7% | -$92.5M-58.6% | -$58.4M |
| Basic net income (loss) per ordinary share (in usd per share) | -$1K+21.8% | -$2K+20.0% | -$2K-121.6% | -$880-57.1% | -$560 |
| Diluted net income (loss) per ordinary share (in usd per share) | -$1K+21.8% | -$2K+20.0% | -$2K-121.6% | -$880-57.1% | -$560 |
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | $111.47B+3.4% | $107.83B+1.4% | $106.39B+1.7% | $104.66B+1.2% | $103.43B |
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | $111.47B+3.4% | $107.83B+1.4% | $106.39B+1.7% | $104.66B+1.2% | $103.43B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry
International Markets and NovoCure (NVCR): A Deep Dive for Investors
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet